Monoethanolamine

Monoethanolamine

SCHEMBL3415017

ClCCl.NCCO

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MPL

The experimentally established mechanism targets of Monoethanolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110078747-A A kind of novel thiazole class drug molecule and preparation method thereof for hospital disinfection 河南科技大学第一附属医院 2019-08-02 CN claimed
US-20240216521-A1 METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES IMMUNOGEN INC (US) 2024-07-04 US disclosed
US-20240197898-A1 SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS IMMUNOGEN, INC. 2024-06-20 US disclosed
US-20240190956-A1 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS IMMUNOGEN INC (US) 2024-06-13 US disclosed
EP-4374850-A2 METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES ImmunoGen, Inc. (US) 2024-05-29 EP disclosed
US-20240165256-A1 METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER IMMUNOGEN INC (US) 2024-05-23 US disclosed
US-RE49918-E1 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2024-04-16 US disclosed
WO-2024059263-A1 METHODS FOR PREPARING MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS IMMUNOGEN, INC. (US) 2024-03-21 WO disclosed
WO-2024059267-A1 IMPROVED METHODS FOR PREPARING N-METHYL ALANINE ESTERS OF MAYTANSINOL IMMUNOGEN, INC. (US) 2024-03-21 WO disclosed
CN-117729942-A Methods for increasing efficacy of ADAM 9-targeted immunoconjugates in the treatment of cancer 伊缪诺金公司 2024-03-19 CN disclosed
US-20100203007-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN INC. (US) 2010-08-12 US disclosed
WO-2010091150-A1 NOVEL BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. (US) 2010-08-12 WO disclosed
US-6828314-B2 Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity PFIZER 2004-12-07 US disclosed
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives PHARMACIA & UPJOHN COMPANY 2003-12-04 US disclosed
US-6586421-B2 For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders PHARMACIA & UPJOHN COMPANY 2003-07-01 US disclosed
EP-1319005-A2 SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES PHARMACIA &amp; UPJOHN COMPANY (US) 2003-06-18 EP disclosed
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives PHARMACIA & UPJOHN COMPANY 2002-06-20 US disclosed
WO-2002024700-A2 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 WO disclosed
US-4966490-A Apparatus for use in applying a thin resinous coating to existing surfaces HODSON CHEMICAL CONSTRUCTION CORPORATION, 1990-10-30 US disclosed
US-4966927-A CURABLE EPOXY RESIN FOR CONCRETE; ETHANOLAMINE-METHYLENE CHLORIDE CURING AGENT HODSON CHEMICAL CONSTRUCTION CORPORATION, 1990-10-30 US disclosed